Date: 28 Dec 2013
Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials
Probiotics have been used for the treatment of inflammatory bowel diseases (IBD). However, the effects of probiotics on the induction and maintenance of remission in ulcerative colitis (UC) or Crohn’s disease (CD) still remain controversial. This systematic review verified the findings of high-quality randomized controlled trials (RCTs) which investigated the therapeutic effects of probiotics on IBD. After the quality assessment, 20 RCTs which investigated the effects of probiotics on the induction or maintenance of remission in IBD were identified. From the results of the validation of these RCTs, beneficial effects of probiotic treatments to improve the response rate and remission rate on the remission induction therapies [risk ratio (RR) 1.81; 95 % confidence interval (CI) 1.40–2.35 and RR 1.56; 95 % CI 0.95–2.56, respectively] were verified. Furthermore, probiotic treatments exhibited effects equal to mesalazine on the maintenance of remission in UC (RR 1.00; 95 % CI 0.79–1.26). In contrast, no significant effect of probiotic treatments was shown in either the induction or maintenance of remission in CD. Because there were many variations in the conditions among these studies, a further analysis evaluating the effects of probiotic treatments in IBD is needed to clarify the optimal probiotics and treatment regimens for each condition or population in IBD patients.
An erratum to this article can be found at http://dx.doi.org/10.1007/s12328-014-0456-8.
Organization WH. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf (2001).
Metchnikoff E. The prolongation of life: optimistic studies. New York: Springer; 2004.
Smits HH, Engering A, van der Kleij D, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005;115:1260–7.PubMedCrossRef
Zhang L, Li N, Caicedo R, et al. Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J Nutr. 2005;135:1752–6.PubMed
Fujiya MKY. Novel perspectives in probiotic treatment: the efficacy and unveiled mechanisms of the physiological functions. Clin J Gastroenterol. 2010;3:11.CrossRef
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0: The Cochrane Collaboration, 2011.
Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004;10:PI126–31.PubMed
Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;4:CD005573.PubMed
Rolfe VE, Fortun PJ, Hawkey CJ, et al. Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2006;4:CD004826.PubMed
Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn’s disease. Cochrane Database Syst Rev. 2009;4:CD006873.PubMed
- Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials
Clinical Journal of Gastroenterology
Volume 7, Issue 1 , pp 1-13
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Inflammatory bowel disease
- Ulcerative colitis
- Crohn’s disease
- Escherichia coli
- Ileal pouch